Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

NCT06888921 is registered in ClinicalTrials.gov with Compugen Ltd as lead sponsor.

NCT NCT06888921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06888921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
Lead sponsor
Compugen Ltd
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 21, 2025
Completion date
March 31, 2027
Enrollment
60 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian cancer recurrent